In short
This article discusses a clinical trial investigating the use of a standardized dry extract of horse chestnut in patients undergoing meniscus surgery. The study aims to evaluate the efficacy and tolerability of this extract in reducing post-operative swelling, edema, and pain. We'll explore the trial's objectives, eligibility criteria, and potential benefits for patients recovering from knee surgery.
At a glance
- Study Drug
- Aescuven® (Dry Extract of Horse Chestnut)
- Dosage
- 4 tablets per day (2 coated tablets twice daily)
- Main Objective
- Reduce post-operative swelling, edema, and pain after meniscus surgery
- Study Design
- Placebo-controlled, randomized, double-blind, single-center, pilot study
- Primary Endpoints
- Knee volume and patient-reported outcome measures
- Secondary Endpoints
- Knee circumference, range of motion, skin temperature, quality of life
- Eligibility Age
- 18-75 years
- Treatment Duration
- Maximum 18 days
What is Horse Chestnut Seed Extract?
Horse Chestnut Seed Extract is a natural substance derived from the seeds of the horse chestnut tree. The specific extract used in this study is standardized and adjusted to contain 12.5 mg of triterpene glycosides, calculated as protoaescigenin, per dose. This extract is the active ingredient in a medication called Aescuven®, which comes in the form of coated tablets.
Medical Conditions Treated
The clinical trial is investigating the use of horse chestnut seed extract for treating several post-operative conditions, including:
- Post-operative swelling: Swelling that occurs after surgery
- Post-operative pain: Pain experienced following a surgical procedure
- Post-operative edema: Excess fluid accumulation in body tissues after surgery
Specifically, the trial focuses on patients who have undergone meniscus surgery, which is a procedure to repair or remove damaged cartilage in the knee joint.
How It Works
While the exact mechanism is not fully explained in the trial information, horse chestnut seed extract is known to have anti-inflammatory and vascular-protective properties. The active compounds, particularly aescin (a mixture of triterpene glycosides), are believed to help reduce swelling and improve circulation.
Clinical Trial Details
The clinical trial is designed as a placebo-controlled, randomized, double-blind, single-center, pilot study. This means:
- Placebo-controlled: Some participants will receive the actual medication, while others will receive a placebo (a substance with no active ingredients)
- Randomized: Participants are randomly assigned to either the treatment or placebo group
- Double-blind: Neither the participants nor the researchers know who is receiving the actual medication or the placebo
- Single-center: The study is conducted at one medical facility
- Pilot study: This is an initial small-scale study to evaluate the feasibility and potential effects of the treatment
Dosage and Administration
In this trial, participants are given Aescuven® at a dose of 4 tablets per day, taken as 2 coated tablets twice daily. The maximum daily dose is 50 mg, and the maximum total dose over the course of treatment is 900 mg. The medication is taken orally, and the maximum treatment period is 18 days.
Potential Benefits
The main objective of the study is to investigate whether Aescuven® can decrease post-operative swelling, edema, and pain after meniscus surgery. Researchers will measure various outcomes, including:
- Volume and circumference of the affected knee
- Range of motion of the knee joint
- Skin temperature at the surgery site
- Volume of drained fluid after knee surgery
- Patient-reported outcomes on pain and quality of life
Eligibility Criteria
To participate in this study, patients must meet certain criteria, including:
- Age between 18 and 75 years
- Scheduled for unilateral knee surgery (meniscus arthroscopy) within 5 months of screening
- Willing and able to follow study instructions and attend all visits
There are also several exclusion criteria, such as pregnancy, certain medical conditions, and use of medications that might interfere with the study results.
Safety Considerations
While horse chestnut seed extract is generally considered safe, the study aims to assess its tolerability and safety specifically for treating swelling after meniscus surgery. Patients with a history of allergy or hypersensitivity to the medication (including lactose intolerance) are excluded from the study.
It's important to note that this is an investigational use of the medication, and its safety and efficacy for this specific purpose are still being evaluated. Patients should always consult with their healthcare provider before starting any new treatment.